Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein degradation pathways to selectively eliminate disease-relevant proteins. The company's approach centers on rational design of oral compounds that employ the ubiquitin-proteasome system to target proteins that have been difficult to drug through conventional mechanisms.

The company's clinical and preclinical pipeline spans multiple therapeutic areas. Lead programs include MRT-2359 for MYC-driven cancers, MRT-6160 for neurologic and systemic autoimmune conditions, and MRT-8102 for IL-1β and NLRP3 inflammasome-driven inflammatory diseases. Additional programs target CDK2 across multiple cancer indications including ovarian, endometrial, gastric, and breast cancers, with further development efforts in immunology, oncology, cardiovascular, metabolic, and genetic disease applications. The company operates QuEEN, a proprietary discovery platform designed to enable systematic identification and optimization of MGD candidates.

Monte Rosa maintains a strategic collaboration with F. Hoffmann-La Roche Ltd. covering MGD discovery and development in cancer and neurological diseases. The company operates with approximately 147 full-time employees and is based in Boston, Massachusetts.